Amgen Inc.

AMGN

US0311621009

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Employees

26,700

Sector

Pharmaceuticals

Calendar

2024-10-28 - Q3 2024 Earnings Release (Projected)

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

320.56USD

Average target price

324.94USD

Spread / Average Target

+1.37%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-06 pm EDT			5-day change	1st Jan Change
320.56 ^USD	-1.17%		-3.98%	+11.30%

Sep. 05	Lantheus Holdings, Inc. Appoints Julie Eastland as Board of Directors	CI
Sep. 05	Transcript : Amgen Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 09:30 AM

Lantheus Holdings, Inc. Appoints Julie Eastland as Board of Directors	Sep. 05	CI
Transcript : Amgen Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 09:30 AM	Sep. 05
Transcript : Amgen Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 09:15 AM	Sep. 04
EyePoint Pharmaceuticals, Inc. Announces Board Changes	Sep. 04	CI
Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India	Sep. 03	CI
Annexon, Inc. Announces Management Appointments	Sep. 03	CI
US will still pay at least twice as much after negotiating drug prices	Sep. 03	RE
Volcano Spring International Holdings Limited Announces Appointment of Zheng Jingwen as Non-Executive Director	Sep. 02	CI
Amgen Says Plaque Psoriasis Drug for Pediatric Use Available in US	Aug. 20	MT
Amgen Announces Otezla®? Now Available in the U.S. for Moderate to Severe Plaque Psoriasis	Aug. 20	CI
Genmab A/S Announces Executive Changes	Aug. 16	CI
US Government Sets Out Prices of 10 Drugs in Medicare Negotiations	Aug. 15	MT
US Government Sets Out Prices of 10 Drugs in Medicare Negotiations	Aug. 15	MT
Top Midday Stories: Walmart Shares Rise on Earnings, Raised Outlook; Biden Administration Releases Prices of 10 Drugs in Medicare Negotiations	Aug. 15	MT
Biden Administration Releases Prices of 10 Drugs in Medicare Negotiations	Aug. 15	MT
Biden Administration Releases Prices of 10 Drugs in Medicare Negotiations	Aug. 15	MT
US announces prices in Medicare drug negotiations	Aug. 15	RE
US expects $6 bln savings from first Medicare drug price negotiations	Aug. 15	RE
Daiwa Securities Adjusts Price Target on Amgen to $351 From $350, Maintains Buy Rating	Aug. 13	MT
Redburn Atlantic Adjusts Amgen Price Target to $180 From $170, Maintains Sell Rating	Aug. 09	MT
UBS Adjusts Price Target on Amgen to $335 From $337, Maintains Neutral Rating	Aug. 08	MT
HSBC Adjusts Price Target on Amgen to $369 From $356	Aug. 08	MT
Sector Update: Health Care Stocks Fall Late Afternoon	Aug. 07	MT
Sector Update: Health Care Stocks Retreat in Afternoon Trading	Aug. 07	MT
Amgen Faces Lawsuit Over Alleged Autoimmune Drug Monopoly	Aug. 07	MT

Amgen Inc.

Equities